Taiwan Proposes New Online Drug Enforcement Obligations Under Pharmaceutical Affairs Act

On June 2, 2026, Taiwan’s Ministry of Health and Welfare (MOHW) published an advance notice of proposed amendments to selected provisions of the Pharmaceutical Affairs Act. The draft introduces a strengthened regulatory framework targeting illegal pharmaceutical advertising, the unlawful online sale of medicines, and the online distribution of counterfeit, prohibited, and unauthorized medicinal products.

While formally structured around internet operators, the proposal is principally aimed at strengthening regulatory control over how medicinal products are promoted, discovered, and sold in digital environments.

For pharmaceutical companies, medical device manufacturers, distributors, and overseas market entrants, the implications extend well beyond platform compliance. The draft effectively reshapes digital market access, advertising exposure, and downstream distribution control in Taiwan.

Why Taiwan Is Tightening Online Pharmaceutical Controls

MOHW cites the rapid expansion of e-commerce, social media, and platform-based healthcare marketing as a key driver for reform. These channels have become a primary route for:

• Illegal pharmaceutical advertising
• Unauthorized online sales of medicines
• Distribution of counterfeit drugs
• Sales of prohibited or unapproved products
• Cross-border online transactions that complicate enforcement

For regulators, the issue is no longer isolated illegal sellers, but the scale and speed of pharmaceutical exposure through digital ecosystems that sit outside traditional compliance oversight.

As a result, enforcement is shifting from targeting end sellers to addressing the platforms and infrastructure that determine product visibility in the first place, with implementation expected across agencies responsible for digital development, communications, education, broadcasting, and science and technology policy.

Platforms Recast as First-Line Pharmaceutical Gatekeepers

The most consequential change lies in proposed Article 79-1, which would impose a “prudent administrator” duty of care on internet operators — including platforms, application providers, and content hosts — for pharmaceutical-related information.

In practice, this turns internet platforms into front-line enforcement actors for pharmaceutical compliance. They will be expected to establish risk-control mechanisms, respond to identified  illegal pharmaceutical content, and remove or restrict access where required under the proposed framework, while benefiting from liability protection when acting in good faith.

For life sciences companies, the implications are indirect but significant:

• Product claims may be pre-screened or downgraded by platform algorithms
• Legitimate promotional content may face stricter compliance filtering
• Product claims and educational materials may require stronger substantiation alignment
• Brand-controlled and third-party content will face more frequent compliance filtering

In effect, platform compliance logic becomes a new layer of de facto pharmaceutical regulation sitting between companies and patients/consumers.

Health Authorities Gain Expanded Visibility into Digital Pharmaceutical Activity

Proposed Article 79-2 significantly expands regulatory oversight into active digital monitoring.

Health authorities would be empowered to use technical tools to proactively identify violations, supported by Taiwan’s digital development agencies. Platforms must cooperate and cannot obstruct inspections.

This shifts enforcement away from reactive complaint handling toward continuous surveillance of digital pharmaceutical environments.

Operators would also be required to retain, for at least 180 days following restriction or removal of the relevant content:

• Webpage and content data
• User identity and account information
• Access logs and usage history

This creates a formal evidentiary layer for enforcement and signals a broader regulatory shift: pharmaceutical-related digital activity is increasingly treated as inspectable compliance data, not transient commercial communication.

This has direct implications for:

• Digital advertising compliance trails
• Influencer and affiliate marketing oversight
• Traceability of online promotional claims
• Distributor-driven online sales activity

24-Hour Takedown Requirement Raises Compliance Pressure

Under proposed Article 79-3, once they become aware of illegal information through  a competent health authority or another government agency, internet operators must remove or restrict access to the relevant content within 24 hours.

This creates a high-speed enforcement environment that will materially affect pharmaceutical communications online.

Platform operators are likely to respond by:

• Over-filtering borderline pharmaceutical content
• Increasing pre-approval requirements for health-related advertising
• Tightening rules around product claims and therapeutic messaging
• Restricting visibility of content lacking clear regulatory substantiation

For pharmaceutical companies, the practical risk is not only enforcement against illegal sellers — it is collateral impact on legitimate but complex or borderline content, including:

• Supplement vs drug positioning
• Off-label discussions in educational content
• Cross-border product communications
• Early-stage product information or pre-launch messaging

Authorities Could Order Internet Access Blocking

Proposed Article 79-4 allows authorities to instruct internet access providers to block access to content within two business days where:

1. The internet operator cannot be identified or contacted.
2. Immediate intervention is necessary to prevent imminent danger or further harm.
3. The operator attempts to evade enforcement through domain changes or similar methods.

This elevates enforcement beyond takedowns into network-level access restriction, particularly targeting offshore or rapidly shifting digital sellers.

 For multinational pharmaceutical companies, this reflects a broader trend: digital pharmaceutical enforcement is no longer confined to jurisdictional boundaries or platform cooperation alone.

Significant Financial Penalties for Non-Compliance

Proposed Article 95-1 introduces administrative fines ranging from NT$200,000 to NT$5,000,000 (approximately US$6,337–158,000) for non-compliance, including evading or obstructing inspections, failing to remove or restrict access to illegal content, failing to retain required records, or failing to comply with internet access blocking obligations.

While directed at intermediaries, the commercial impact will cascade through the ecosystem:

• Increased conservative interpretation of pharmaceutical content rules
• Higher risk scoring for drug-related keywords and claims
• Stricter onboarding of pharma advertisers and sellers
• Greater reliance on pre-approved or verified medical content only

In practice, platform risk aversion becomes a structural constraint on pharmaceutical digital marketing in Taiwan.

What This Means for Pharmaceutical Companies: A Shift in Digital Market Access Risk

Although the amendments are formally aimed at internet operators, the strategic impact for pharmaceutical and life sciences companies is broader and more structural.

Three key shifts emerge:

Digital Visibility Becomes a Regulated Variable

Product discoverability online will increasingly depend on platform compliance logic, not just marketing strategy.

Downstream Actors Become Compliance Exposure Points

Distributors, affiliates, and third-party sellers become regulatory exposure points for the brand, even without direct control.

Cross-Border Marketing Risk Increases Materially

Overseas companies face increased scrutiny of product claims, authorization status, and online distribution pathways into Taiwan.

For pharmaceutical, medical device, and health product companies, this means one thing clearly: online compliance is becoming inseparable from market access strategy.

Final Thoughts

Taiwan’s proposed amendments to the Pharmaceutical Affairs Act signal a structural shift in pharmaceutical regulation as internet infrastructure becomes increasingly integrated into pharmaceutical regulatory enforcement, moving oversight from product-level control toward ecosystem governance of digital pharmaceutical activity.

For pharmaceutical companies, the key shift is the convergence of commercial execution and compliance exposure in digital environments. What has traditionally been treated as marketing infrastructure is increasingly part of the regulatory perimeter, creating new compliance considerations across advertising governance, third-party distribution, and cross-border online activity that may not be fully addressed by existing compliance frameworks.

Cisema supports pharmaceutical, medical device, and life sciences companies navigating evolving regulatory frameworks across Taiwan and broader Asian markets, including Regulatory Affairs, Quality Management & Compliance, and market entry strategy.

To assess the impact of these developments on your products and digital compliance exposure, contact Cisema today.

Further Information

• Explore Cisema’s pharmaceutical consulting services.

References

• Announcement of draft amendments to certain articles of the Pharmaceutical Affairs Act